Adc Therapeutics Ltd Stock News

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report finan

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.

On Vertex Pharmaceuticals' (VRTX) Q2 earnings call, investors are most likely to focus on the sales performance of its cystic fibrosis (CF) medicines and updates on its non-CF pipeline candidates.

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADC Therapeutics SA (ADCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Centene's (CNC) second-quarter results are likely to reflect growth in premiums.

Teladoc Health's (TDOC) second-quarter results are likely to reflect growth in Subscription Access Fees.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healt

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the l

ADCT earnings call for the period ending March 31, 2022.

ADC Therapeutics SA (NYSE:ADCT ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Chris Martin - Former Chief Executive Officer

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.